Search

Displaying results 1791 - 1800 of 10000 in total
  1. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … [A245154] Notably, none of these agents are approved for use in the treatment of CAD.

  2. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

  3. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  4. Drug

    rdESAT-6

    go.drugbank.com/drugs/DB21906
    Approved

    rdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]

  5. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    [A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in

    International brands: Kalymin N
  6. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell

  7. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

  8. Drug

    Tranylcypromine

    go.drugbank.com/drugs/DB00752
    ApprovedInvestigational

    An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine). … It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).

  9. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … [A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the

    Synonyms: N-Hydroxyurea, N-Carbamoylhydroxylamine
  10. Drug

    Moexipril

    go.drugbank.com/drugs/DB00691
    ApprovedInvestigational

    Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen...

    Categories: Agents Acting on the Renin-Angiotensin System